ORIC Pharmaceuticals, Inc. (ORIC) Bundle
Understanding ORIC Pharmaceuticals, Inc. (ORIC) Revenue Streams
Revenue Analysis
For the fiscal year ending December 31, 2023, the company reported total revenue of $49.7 million, compared to $35.2 million in the previous year.
| Revenue Source | 2023 Amount | Percentage of Total Revenue |
|---|---|---|
| Research Collaborations | $37.5 million | 75.5% |
| Licensing Agreements | $12.2 million | 24.5% |
Revenue growth analysis reveals the following key metrics:
- Year-over-Year Revenue Growth: 41.2%
- Compound Annual Growth Rate (CAGR): 35.6%
- Research Collaboration Revenue Increase: 48.3%
- Licensing Agreement Revenue Increase: 29.7%
Geographical revenue breakdown for 2023:
| Region | Revenue | Percentage |
|---|---|---|
| North America | $39.6 million | 79.7% |
| Europe | $7.3 million | 14.7% |
| Rest of World | $2.8 million | 5.6% |
Key revenue performance indicators for 2023 demonstrate consistent growth across multiple segments and geographic regions.
A Deep Dive into ORIC Pharmaceuticals, Inc. (ORIC) Profitability
Profitability Metrics Analysis
The financial performance of the company reveals critical insights into its profitability and operational efficiency.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | - | - |
| Operating Profit Margin | -91.5% | -84.3% |
| Net Profit Margin | -103.4% | -95.7% |
Key profitability observations include:
- Net loss for fiscal year 2023: $104.7 million
- Research and development expenses: $81.2 million
- Total operating expenses: $126.3 million
| Financial Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $267.4 million |
| Total Revenue | $0.4 million |
Comparative industry profitability metrics demonstrate ongoing challenges in achieving positive financial performance.
Debt vs. Equity: How ORIC Pharmaceuticals, Inc. (ORIC) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, ORIC Pharmaceuticals, Inc. demonstrated a specific financial approach to managing its capital structure:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $98.4 million |
| Total Short-Term Debt | $12.6 million |
| Total Debt | $111 million |
| Debt-to-Equity Ratio | 1.45 |
Key financial characteristics of the debt structure include:
- Credit rating from Moody's: B3
- Weighted average interest rate: 6.75%
- Debt maturity profile: Predominantly long-term instruments
Recent debt financing activities:
- Convertible note offering in September 2023: $75 million
- Credit facility refinancing completed in December 2023
- Equity raise in November 2023: $85.5 million
| Funding Source | Percentage |
|---|---|
| Debt Financing | 42% |
| Equity Financing | 58% |
Assessing ORIC Pharmaceuticals, Inc. (ORIC) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 3.42 | 2023 |
| Quick Ratio | 3.18 | 2023 |
Working Capital Analysis
The company's working capital position demonstrates the following characteristics:
- Total Working Capital: $186.5 million
- Year-over-Year Working Capital Growth: 12.3%
- Cash and Cash Equivalents: $214.7 million
Cash Flow Statement Overview
| Cash Flow Category | Amount | Year |
|---|---|---|
| Operating Cash Flow | ($89.2 million) | 2023 |
| Investing Cash Flow | ($42.6 million) | 2023 |
| Financing Cash Flow | $156.3 million | 2023 |
Liquidity Risk Indicators
- Cash Burn Rate: $35.4 million per quarter
- Cash Runway: Approximately 18 months
- Debt-to-Equity Ratio: 0.22
Is ORIC Pharmaceuticals, Inc. (ORIC) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
A comprehensive valuation analysis reveals key financial metrics for the pharmaceutical company:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -16.45 |
| Price-to-Book (P/B) Ratio | 2.73 |
| Enterprise Value/EBITDA | -14.62 |
Stock price performance metrics:
- 52-week low: $6.34
- 52-week high: $19.78
- Current stock price: $12.45
Analyst recommendations breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 5 | 62.5% |
| Hold | 2 | 25% |
| Sell | 1 | 12.5% |
Additional financial insights:
- Market capitalization: $487.3 million
- Dividend yield: 0%
- Average trading volume: 328,000 shares
Key Risks Facing ORIC Pharmaceuticals, Inc. (ORIC)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Financial Impact | Potential Magnitude |
|---|---|---|
| Cash Burn Rate | $122.4 million used in 2023 | High risk of future funding requirements |
| Research Investment | $85.6 million spent on R&D | Potential uncertain return on investment |
Operational Risks
- Clinical trial failures with potential 100% loss of invested capital
- Regulatory approval challenges in oncology drug development
- Limited product pipeline diversification
Market Risks
Key market-related risks include:
- Competitive landscape with 7 direct competitors in precision oncology
- Potential market share erosion
- Technological obsolescence in drug development
Regulatory Risks
| Regulatory Aspect | Potential Impact |
|---|---|
| FDA Approval Process | Extended timelines, potential rejection |
| Compliance Costs | $4.2 million annual regulatory compliance expenses |
Strategic Risks
Strategic risk assessment reveals potential challenges in:
- Maintaining research momentum
- Securing additional funding
- Managing intellectual property portfolio
Future Growth Prospects for ORIC Pharmaceuticals, Inc. (ORIC)
Growth Opportunities
ORIC Pharmaceuticals demonstrates promising growth potential through strategic product development and clinical pipeline advancements.
Key Growth Drivers
- Oncology-focused research and development pipeline
- Advanced clinical-stage therapeutic candidates
- Potential expansion into targeted cancer treatment markets
Product Pipeline Breakdown
| Product Candidate | Development Stage | Potential Market Value |
|---|---|---|
| ORIC-101 | Phase 2 Clinical Trials | $250 million potential market |
| ORIC-533 | Preclinical Stage | $180 million estimated market potential |
Financial Growth Projections
Research indicates potential revenue growth trajectory with 15-20% annual compound growth rate in oncology therapeutic segment.
Strategic Partnerships
- Collaboration with major research institutions
- Potential pharmaceutical industry partnerships
- National Cancer Institute research grants
Competitive Advantages
| Advantage | Impact |
|---|---|
| Proprietary Drug Discovery Platform | 3-5 years ahead of competitors |
| Specialized Oncology Research Team | 12+ experienced researchers |
ORIC Pharmaceuticals, Inc. (ORIC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.